Ken Griffin Aadi Bioscience, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.32 - $2.06 $19,008 - $29,664	14,400 Added 153.19%	23,800 $49,000
Q2 2024 Aug 14, 2024	BUY	$1.46 - $2.31 $6,570 - $10,395	4,500 Added 91.84%	9,400 $13,000
Q1 2024 May 15, 2024	SELL	$1.59 - $2.44 $10,335 - $15,860	-6,500 Reduced 57.02%	4,900 $11,000
Q4 2023 Feb 14, 2024	BUY	$1.97 - $5.41 $2,758 - $7,574	1,400 Added 14.0%	11,400 $23,000
Q3 2023 Nov 14, 2023	SELL	$4.84 - $7.13 $152,460 - $224,595	-31,500 Reduced 75.9%	10,000 $48,000
Q2 2023 Aug 14, 2023	BUY	$6.84 - $8.56 $275,652 - $344,968	40,300 Added 3358.33%	41,500 $283,000
Q1 2023 May 15, 2023	SELL	$6.85 - $13.0 $487,035 - $924,300	-71,100 Reduced 98.34%	1,200 $8,000
Q4 2022 Feb 14, 2023	SELL	$11.99 - $14.5 $738,584 - $893,200	-61,600 Reduced 46.0%	72,300 $927,000
Q3 2022 Nov 14, 2022	SELL	$12.03 - $14.22 $146,766 - $173,484	-12,200 Reduced 8.35%	133,900 $1.89 Million

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $67.5M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.